Online Course

Advanced eBytes: Spondyloarthritis: Classification and Epidemiology

Date:

Expires Jan 4, 2022

Program Information

CME: 0.5

Advanced Rheumatology eBytes were created to compliment the Advanced Rheumatology Course by allowing you to get a “bite-size” of education while receiving CME credits at any time that is convenient for you. Free for ACR/ARP members!

63% of Axial Spondyloarthritis (AS) patients received their diagnosis from a non-rheumatologist and only 42% with an initial diagnosis of AS by a non-rheumatologist had their diagnosis confirmed by a rheumatologist. Median delay from back-pain diagnosis to rheumatologist referral was 10 months; time from referral to AS diagnosis was 1 month.   Interested in learning more, register for this activity and complete it during your lunch hour.

Includes the following:

  • Audio presentation
  • Post assessment
  • Activity evaluation
  • AMA PRA Category 1 Credits™ with a passing score of 70% or higher

Target Audience
The target audience is physicians, fellows-in-training, nurse practitioners, physician assistants, nurses, practice managers, physical therapists, occupational therapists, pharmacists, and medical and health professional students involved in the care of patients with rheumatic disease.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the population prevalence of axial Spondyloarthritis in the United States and compare it with rheumatoid arthritis
  • Discuss the difference between diagnostic and classification criteria and the pitfalls of using the classification criteria for making the diagnosis

Registration Fees

Free for ACR/ARP members. Not a member? Join today. ARP membership ranges from $30 - $140 per year.

  • Member: $0
  • Non-Member: $50

CME and MOC Information

Accreditation Statement 
The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement 
The American College of Rheumatology designates this enduring online activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Health Professionals 
Participants may claim credit and receive a Certificate of Participation for this activity.

Faculty and Disclosures

ACR Disclosure Statement
The ACR is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. Educational activities provided by the ACR must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias.

Faculty participating in an ACR-sponsored activity must disclose to the editorial team and audience any financial or other relationship(s) including, but not limited to:

  1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
  2. Research grants
  3. Employment (full or part-time)
  4. Ownership or partnership
  5. Consulting fees or other remuneration (payment)
  6. Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson
  7. Receipt of royalties
  8. Speakers' bureau
  9. Other

The faculty reported the following disclosures:

Scientific Editor
Benjamin J Smith, PA-C, DFAAPA - No relevant financial relationships to disclose

Associate Editors

  • Atul Deodhar, MD, MRCP - Amgen, GSK, Sun Pharma², Eli Lilly, Janssen, Novartis, Pfizer, UCB2, 5
  • Kori A. Dewing, DNP, ARNP – Abbvie5

Managing Editors

  • Emily Delzell - No relevant financial relationships to disclose
  • Anneke Smith, MS - No relevant financial relationships to disclose

Author
Atul Deodhar, MD, MRCP – Amgen, GSK, Sun Pharma², Eli Lilly, Janssen, Novartis, Pfizer, UCB ² 5

Reviewer
Christopher Ritchlin, MD, MPH – Abbvie, Amgen, UCB2 Abbvie, Amgen, UCB, Novartis, Pfizer, Janssen5

Contact Info / Inquiries

rhilliard@rheumatology.org
404-633-3777, ext. 808